<span identification=”midArticle_start”/><span identity=”midArticle_0″/> (Reuters) – Early-stage trials of anexperimental Ebola vaccine, two in the USA and 4 inAfrica and Europe, have discovered that it seems to be secure andtriggered tough manufacturing of Ebola-combating antibodies,scientists pronounced on Wednesday.
<span identification=”midArticle_1″/>Seeing that trials can not ethically expose volunteers to Ebola,the manufacturing of antibodies is a proxy for whether or not vaccinescould stop and even deal with the disease.
<span id=”midArticle_2″/>There is currently no vaccine or specific treatment forEbola, which has killed over 10,000 people in West Africa sincelast spring, according to the World Health Organization. It isthe worst Ebola epidemic in history, but finally appears to beabating.
<span id=”midArticle_3″/>The trials all tested a vaccine called VSV-ZEBOV, which wasdeveloped at the Public Health Agency of Canada and licensed toNewLink Genetics Corp and then to Merck & Co Inc. It consists of a cattle virus called rVSV that has beenengineered to carry Ebola genes, which produce proteins meant totrigger production of anti-Ebola antibodies.
<span id=”midArticle_4″/>According to separate teams of scientists, that is whathappened, two papers in the New England Journal of Medicinereported.
<span id=”midArticle_5″/>In the U.S. trials, conducted independently butcooperatively at the National Institutes of Health and theWalter Reed Army Institute of Research starting last October, 52healthy adult volunteers received single injections of saline oreither of two doses of vaccine.
<span id=”midArticle_6″/>The most common side effects were mild, such as pain at theinjection site and short-lived fever. All 40 participants whoreceived vaccine produced anti-Ebola antibodies within 28 days,with most responding sooner.
<span id=”midArticle_7″/>The higher dose triggered triple the antibody response ofthe lower dose. The “robust” response to a single dose “could beparticularly useful in outbreak interventions,” said WalterReed’s Col. Stephen Thomas, senior author of the U.S. paper.
<span id=”midArticle_8″/>The higher dose is being tested in a larger trial inLiberia. Partly through that trial, both VSV-ZEBOV and anexperimental vaccine from GlaxoSmithKline PLC calledcAd3-EBOZ “appear to be safe,” NIH announced last week.[IDn:L2N0WS2WN]
<span id=”midArticle_9″/>The other studies were similarly encouraging.
<span id=”midArticle_10″/>In coordinated trials in Germany, Switzerland, Gabon andKenya, 158 healthy volunteers received a placebo or any of fivedose-levels of VSV-ZEBOV vaccine.
<span id=”midArticle_11″/>Although the Geneva study was temporarily halted last yearafter 11 of 51 participants developed arthritis, overall therewere “no serious vaccine-related adverse events,” theresearchers pronounced. All a hundred and fifty individuals who got vaccinedeveloped antibodies to Ebola with larger responses to higherdoses. (Reporting by means of Sharon Begley, enhancing via G Crosse)
<span identity=”midArticle_12″/>
The post Merck, NewLink Ebola vaccine seems protected, efficient in new research appeared first on Smart Health Shop Blog.
via Smart Health Shop Blog http://ift.tt/1GMU836
No comments:
Post a Comment